The FDA has given its stamp of approval on the first new drug approved for prostate cancer in four years.
Wired PR News.com – A new drug used to treat prostate cancer was recently granted approval by the Food and Drug Administration (FDA). As reported by the Associated Press (AP), the injectable drug manufactured by Ferring Pharmaceuticals works by lowering testosterone levels, which is a change from some traditional medications that have been shown to increase the production of testosterone, which may facilitate the growth of prostate tumors.
Richard Pazdur of the FDA was quoted in the report as stating, “Prostate cancer is the second leading cause of cancer death among men in the United States and there is an ongoing need for additional treatment options.” Statistics have shown prostate cancer to affect an estimated 190,000 men each year.
The drug, called degarelix, is said to leave testosterone levels comparable to that of patients whose testes have been removed. The FDA approval was the first granted in 4 years by the agency for a new prostate cancer drug.
Photo Credit: © www.mysona.dk